SCHEMBL7768050

SCHEMBL7768050

O=C(c1ccc(Cc2ccccc2)cc1)N1CCC(C2CN(C(=O)c3ccccc3)C2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.57
KMT2A Q03164 3/20 0.53
ACHE P22303 1/20 0.52
EPHX1 P07099 1/20 0.52
CHRNB2 P17787 1/20 0.51
CHRNB4 P30926 1/20 0.51
CHRNA3 P32297 1/20 0.51
CHRNA7 P36544 1/20 0.51
CHRNA4 P43681 1/20 0.51
L3MBTL3 Q96JM7 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GAA P10253 1/20 0.48
HTT P42858 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
HTR1A P08908 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7762271 0.83 L3MBTL3 (0.56) MGLLKMT2AACHEEPHX1CHRNB2
SCHEMBL693648 0.81 KDM4E (0.56) MGLLKMT2AL3MBTL3L3MBTL1MEN1
SCHEMBL2132236 0.81 EPHX1 (0.56) MGLLKMT2AACHEEPHX1GAA
SCHEMBL2130381 0.81 EPHX1 (0.56) MGLLKMT2AACHEEPHX1GAA
SCHEMBL2135026 0.79 HRH3 (0.51) MGLLKMT2AACHEEPHX1L3MBTL3
SCHEMBL3917660 0.77 KDM4E (0.68) L3MBTL3L3MBTL1KDM4EALDH1A1
SCHEMBL2884997 0.76 L3MBTL3 (0.71) L3MBTL3L3MBTL1
SCHEMBL4765933 0.76 L3MBTL3 (0.71) L3MBTL3L3MBTL1
SCHEMBL17953046 0.76 KDM4E (0.61) KMT2ACHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL693330 0.76 SIGMAR1 (0.73) MGLLKMT2AMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445477-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2013-05-21 US disclosed
US-8445477-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2013-05-21 US disclosed
US-20100324012-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed
US-20100324012-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324012-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MGLL 5/4885KMT2A 1573/4885ACHE 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.